Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CG200745,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer
Details : Ivaltinostat is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase. It is being developed for the treatment of metastatic pancreatic ductal adenocarcinoma.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Lead Product(s) : CG200745,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?